ciprofloxacin and Escherichia coli Infections studies

Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

Escherichia coli Infections: Infections with bacteria of the species ESCHERICHIA COLI.

Research Excerpts

Excerpt	Relevance	Reference
"We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women."	9.51	Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. ( Bonten, MJM; Branger, J; Geerlings, SE; Hassing, RJ; Hoepelman, AIM; Ketels, T; Koldewijn, EL; Koster, A; Kuiper, S; Ten Doesschate, T; van den Bijllaardt, W; van der Bij, AK; van Mens, SP; van Nieuwkoop, C; van Werkhoven, CH, 2022)
"The novel oral antibiotic formulation Rifamycin SV-MMX®, with a targeted delivery to the distal small bowel and colon, was superior to placebo in treating travellers' diarrhea (TD) in a previous study."	9.27	Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria. ( Araujo, P; DuPont, HL; Gracias Garcia, ML; Greinwald, R; Jiang, ZD; Nacak, T; Steffen, R; Stiess, M, 2018)
"Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis."	9.16	Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. ( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012)
"The fecal flora obtained from 13 patients with ulcerative colitis was examined at the beginning of a pouchitis episode before treatment, during treatment with metronidazole or ciprofloxacin, and during pouchitis-free periods."	9.11	Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. ( Gosselink, MP; Hop, WC; Laman, JD; Ruseler-van Embden, JG; Schouten, WR; van Lieshout, LM, 2004)
"The purpose of this study was to determine the role of enteroaggregative Escherichia coli (EAEC) in the development of traveler's diarrhea and the clinical response of patients with EAEC diarrhea following treatment with ciprofloxacin."	9.09	Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. ( Adachi, JA; Ashley, D; DiCesare, D; DuPont, HL; Ericsson, CD; Glandt, M; Jiang, ZD; Mathewson, JJ, 1999)
"The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany."	9.09	Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000)
"To investigate the effects of an intravenous injection of tobramycin (T) in female patients with acute uncomplicated pyelonephritis treated with ciprofloxacin (CIP) (500 mg bid per os)."	9.09	[Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin]. ( Baron, D; Bonnieux, J; Bourrier, P; Le Conte, P; Lebrin, P; Merit, JB; Potel, G; Simon, N, 2001)
"We compare the bacteriological and clinical efficacy of rufloxacin and ciprofloxacin in patients with acute uncomplicated pyelonephritis."	9.08	Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. ( Bach, D; Cesana, M; Hübner, A; Plétan, Y; van Breukelen, G; van den Berg-Segers, A, 1995)
"The efficacy and safety of two fluoroquinolone antimicrobial agents, lomefloxacin and ciprofloxacin, were compared in a randomized, investigator-blinded, multiple-dose study that enrolled 150 adult outpatients with complicated or recurrent urinary tract infections."	9.07	A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. ( Cox, CE, 1992)
"To determine the efficacy of loperamide given with long- and short-course quinolone therapy for treating traveler's diarrhea, 142 US military personnel were randomized to receive a single 750-mg dose of ciprofloxacin with placebo, 750 mg of ciprofloxacin with loperamide, or a 3-day course of 500 mg of ciprofloxacin twice daily with loperamide."	9.07	Treatment of traveler's diarrhea with ciprofloxacin and loperamide. ( DeFraites, R; Echeverria, P; Gelnett, J; Haberberger, RL; Murphy, GS; Petruccelli, BP; Sanchez, JL; Taylor, DN; Walz, S, 1992)
"A prospective, randomised trial was undertaken to compare the efficacy of ciprofloxacin and netilmicin for the treatment of acute pyelonephritis."	9.07	Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. ( Bailey, RR; Lynn, KL; Peddie, BA; Robson, RA; Smith, A, 1992)
"To compare the safety and efficacy of loperamide used in combination with ciprofloxacin or ciprofloxacin alone for the treatment of travelers' diarrhea."	9.07	Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. ( Candler, W; Echeverria, P; McQueen, C; Sanchez, JL; Taylor, DN; Thornton, S, 1991)
"The clinical efficacy and tolerability of ciprofloxacin orally administered at the dosage of 250 mg twice a day was evaluated in 25 patients affected by acute bacterial pharyngotonsillitis."	9.06	Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis. ( D'Errico, G; Esposito, S; Montanaro, C, 1990)
"Two single-dose regimens of ciprofloxacin, 100 and 250 mg, were compared in the treatment of uncomplicated urinary tract infections in women."	9.06	Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. ( Flepp, M; Garlando, F; Lüthy, R; Meier, B; Rietiker, S; Täuber, MG, 1987)
"In a one-year follow-up study, short-term therapy with ciprofloxacin proved to be beneficial in the treatment of chronic bacterial prostatitis, particularly in cases of Escherichia coli prostatitis."	9.06	Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. ( Dalhoff, A; Schiefer, HG; Weidner, W, 1987)
"In a prospective, randomized, double-blind trial, ciprofloxacin (250 mg orally, twice daily) was compared with cinoxacin (500 mg orally, twice daily) in 60 patients with urinary tract infections."	9.06	Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. ( Alpert, ML; Citron, DM; Ginsberg, BP; Goldstein, EJ; Greenway, FL; Kahn, RM, 1987)
"These cases illustrate that cefoxitin is an interesting alternative to carbapenems, even in severe infections such as endocarditis."	8.12	Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis. ( Courtois, R; Danneels, P; Dubée, V; Eveillard, M; Kempf, M; Mahieu, R; Quinqueneau, C; Rihet, C; Vannier, C, 2022)
"To evaluate the impact of cessation of ciprofloxacin prophylaxis during stem cell transplantation for multiple myeloma."	7.91	Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. ( Gabalec, F; Paterova, P; Radocha, J; Zak, P; Zavrelova, A, 2019)
"Korean red ginseng (KRG) may be a beneficial adjuvant along with ciprofloxacin to ameliorate devastating effects of epididymo-orchitis (EO) on male fertility."	7.85	Co-administration of ginseng and ciprofloxacin ameliorates epididymo-orchitis induced alterations in sperm quality and spermatogenic cells apoptosis following infection in rats. ( Eskandari, M; Eyni, H; Ghalyanchi Langeroudi, A; Kazemi, M; Rostami, A; Shokri, S; Zeighami, H, 2017)
"Antimicrobial resistance to ciprofloxacin is rising worldwide, especially in bacteria causing urinary tract infections (UTIs)."	7.85	Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population. ( de Visser, H; Goessens, WH; Hofman, A; Kiefte-de Jong, JC; Mulder, M; Stricker, BH; Verbon, A, 2017)
"The Infectious Diseases Society of America guidelines recommend either 14 days of trimethoprim-sulfamethoxazole (TMP-SMX) or 7 days of ciprofloxacin for the treatment of pyelonephritis."	7.85	A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis. ( Conley, AT; Fox, MT; Melia, MT; Same, RG; Tamma, PD, 2017)
"In this prospective audit, patients were identified as having a low- or high-risk of sepsis based on a questionnaire about established risk factors: previous biopsy; recurrent urine infections; receiving ciprofloxacin in the 12 months prior; travel to South-East Asia or South America in the previous 6 months; or diabetes, immune system impairment or receipt of immunosuppressant drugs."	7.80	Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. ( Blackmore, T; Losco, G; Studd, R, 2014)
" In this patient, however, the clinical course was dramatically complicated by the development of ciprofloxacin-associated rhabdomyolysis."	7.79	Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis. ( Fruhwald, S; Grisold, AJ; Hoenigl, M; Ovcina, I; Valentin, T, 2013)
"Of the 24 patients with EHEC-associated diarrhea, seven received antibiotics before any signs of HUS were present (ciprofloxacin, cefotaxime, amoxicillin and/or metronidazole)."	7.79	Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4-associated diarrhea. ( Fritzsche, C; Geerdes-Fenge, HF; Henschel, J; Höhn, R; Koball, S; Löbermann, M; Mitzner, S; Nürnberg, M; Podbielski, A; Reisinger, EC; Schober, HC, 2013)
"To clarify the characteristics of the virulence factors (VFs) of ciprofloxacin resistant Escherichia coli (CFRE) with acute uncomplicated cystitis (AUC), we determined the VFs and the phylogenetic background of all 54 CFRE strains and the 55 randomly selected ciprofloxacin sensitive E."	7.76	Virulence characteristics and phylogenetic background of ciprofloxacin resistant Escherichia coli in the urine samples from Korean women with acute uncomplicated cystitis. ( Cho, IR; Cho, YH; Kim, CS; Kim, ME; Lee, G, 2010)
"Pregnant rabbits were treated with ciprofloxacin alone or with gentamicin in a model of Escherichia coli chorioamnionitis, and the results were compared with those for untreated rabbits."	7.75	Efficacy of ciprofloxacin in an experimental model of Escherichia coli chorioamnionitis in rabbits. ( Caillon, J; Gras-Le Guen, C; Jacqueline, C; Joram, N; Launay, E; Miegeville, AF; Potel, G; Roze, JC, 2009)
"The aims of this study were to investigate the prevalence of qnrA, qnrB, and qnrS determinants and their molecular characteristics in ciprofloxacin-resistant isolates of Escherichia coli and Klebsiella pneumoniae from urinary tract infections (UTI) in Korea."	7.74	High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections in Korea. ( Chang, CL; Jung, HJ; Kim, HR; Lee, JN; Lee, JY; Shin, JH, 2008)
"Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E."	7.74	In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. ( Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007)
"The aim of this study was to evaluate the efficiency of methylene blue (MB) in preventing renal scar formation after the induction of pyelonephritis (PNP) in a rat model with delayed antimicrobial therapy."	7.74	The effects of methylene blue on renal scarring due to pyelonephritis in rats. ( Aksu, B; Aydin, S; Ayvaz, S; Durmus-Altun, G; Gurcan, S; Inan, M; Kanter, M; Oz Puyan, F; Pul, M; Uzun, H, 2007)
"We investigated the effects of epididymo-orchitis and ciprofloxacin on rat testicular histology and spermatogenesis."	7.74	Effect of experimentally induced Escherichia coli epididymo-orchitis and ciprofloxacin treatment on rat spermatogenesis. ( Demir, A; Findik, A; Onol, FF; Sirvanci, S; Tarcan, T; Türker, P, 2007)
"The current results suggest that fluoroquinolone prophylaxis for patients with febrile neutropenia may be abandoned safely in areas with a high prevalence of ciprofloxacin-resistant enterobacteria."	7.72	Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. ( Dalmau, D; Estany, C; Estrada, C; Garau, J; Gomez, L; Marquez, M; Martí, JM; Xercavins, M, 2003)
"The emergence and evolution of quinolone-resistant Escherichia coli in faeces of patients with prostatitis treated with high-dose oral ciprofloxacin for 1 month were studied."	7.71	Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. ( Horcajada, JP; Martínez, JA; Mensa, J; Moreno-Martínez, A; Ruiz, J; Sánchez, M; Soriano, E; Vila, J, 2002)
"To detect if isolates susceptible to quinolones already carry mutations in the gyrA and parC genes, we selected 12 ciprofloxacin-susceptible Escherichia coli strains collected from patients with urinary tract infections in Latin America in 1998, as part of ongoing SENTRY Antimicrobial Surveillance Program."	7.70	Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. ( Gales, AC; Gordon, KA; Jones, RN; Pfaller, MA; Wilke, WW, 2000)
"A total of 16 men suffering from refractory chronic bacterial prostatitis caused by Escherichia coli was treated with ciprofloxacin for 4 weeks."	7.68	Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months. ( Brähler, E; Schiefer, HG; Weidner, W, 1991)
"The ciprofloxacin efficacy was compared to that of tobramycin in an Escherichia coli pyelonephritis model in rat."	7.68	Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin. ( Grise, G; Le Boete, I; Lecomte, F; Lemeland, JF; Thauvin-Eliopoulos, C, 1990)
"Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa."	7.67	Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986)
"Ciprofloxacin was used for the treatment of refractory chronic bacterial prostatis."	6.67	Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin. ( Schiefer, HG; Weidner, W, 1991)
" The use of antibiotics with favourable pharmacokinetic/pharmacodynamic profiles and convenient dosing schedules, which effectively increase bacterial eradication and patient compliance, can help to curb the current epidemic of resistance and reduce the rate of clinical failure associated with resistance."	6.42	Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. ( Elkharrat, D; Naber, KG; Palou, J; Talan, DA, 2004)
"We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women."	5.51	Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. ( Bonten, MJM; Branger, J; Geerlings, SE; Hassing, RJ; Hoepelman, AIM; Ketels, T; Koldewijn, EL; Koster, A; Kuiper, S; Ten Doesschate, T; van den Bijllaardt, W; van der Bij, AK; van Mens, SP; van Nieuwkoop, C; van Werkhoven, CH, 2022)
"Cefepime is a fourth-generation cephalosporin that is widely prescribed with few severe adverse reactions reported."	5.42	Cefepime induced acute interstitial nephritis--a case report. ( Chavada, R; Howlin, K; Mac, K; Paull, S; Wong, J, 2015)
"The antibiotic treatment rate of chronic bacterial prostatitis (CBP) is low, and long-term administration can result in adverse events and bacterial resistance."	5.38	Preventive effect of selenium on chronic bacterial prostatitis. ( Cho, YH; Ha, US; Kim, HW; Kim, SJ; Lee, SJ; Woo, JC; Yoon, BI, 2012)
" However, the treatment outcome is not ideal and long-term administration of antibiotics can result in adverse effects and bacterial resistance."	5.35	Synergistic effect between lycopene and ciprofloxacin on a chronic bacterial prostatitis rat model. ( Cho, YH; Han, CH; Kang, SH; Kim, SW; Sohn, DW; Yang, CH, 2008)
"The novel oral antibiotic formulation Rifamycin SV-MMX®, with a targeted delivery to the distal small bowel and colon, was superior to placebo in treating travellers' diarrhea (TD) in a previous study."	5.27	Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria. ( Araujo, P; DuPont, HL; Gracias Garcia, ML; Greinwald, R; Jiang, ZD; Nacak, T; Steffen, R; Stiess, M, 2018)
"coli urinary tract infections as Alternative Stepdown Treatment) is a randomized, double-blind, double-dummy, non-inferiority trial in which 240 patients will be randomly allocated to a stepdown treatment with FT or ciprofloxacin (standard of care) for FUTI, caused by Escherichia coli with in vitro susceptibility to both antibiotics."	5.27	Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST). ( Bonten, MJM; Geerlings, SE; Hoepelman, AIM; Ten Doesschate, T; van Mens, SP; van Nieuwkoop, C, 2018)
" Adverse reactions were spontaneously reported by four of the 28 patients (14%) and by 11 (39%) after detailed inquiry."	5.27	Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. ( Boerema, J; Boll, B; Branolte, J; Muytjens, H, 1985)
"Ciprofloxacin was tested in the acute and chronic experimental E."	5.27	[Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats]. ( Boness, J; Marre, R; Schulz, E; Tietgen, K, 1986)
" The dosage was 2 X 500 mg ciprofloxacin orally every 12 h for 7."	5.27	Is pelvic inflammatory disease an indication for treatment with ciprofloxacin? ( Chyský, V; Hägele, D, 1988)
"Treatment with ciprofloxacin at 0."	5.27	Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. ( Bloom, R; Fu, KP; Gregory, FJ; Hung, PP; Vince, T, 1987)
"Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis."	5.16	Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. ( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012)
"The objective of this multicenter, randomized, controlled, parallel group trial was to evaluate the efficacy of levofloxacin 250 mg oral, once daily (LVFX), placebo one tablet oral once daily (Placebo [P] group) and ciprofloxacin (CPFX) 500 mg oral, twice daily (single blind), prophylaxis in preventing bacteriuria (> or = 10(3) CFU/ml) in post-surgical catheterized patients."	5.12	A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones. ( Drago, L; Esposito, S; Leone, S; Marchetti, F; Marvaso, A; Noviello, S, 2006)
"The fecal flora obtained from 13 patients with ulcerative colitis was examined at the beginning of a pouchitis episode before treatment, during treatment with metronidazole or ciprofloxacin, and during pouchitis-free periods."	5.11	Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. ( Gosselink, MP; Hop, WC; Laman, JD; Ruseler-van Embden, JG; Schouten, WR; van Lieshout, LM, 2004)
"The study was undertaken to compare the safety and efficacy of twice-daily ciprofloxacin for 3 days with standard 7 day therapy with either co-trimoxazole or nitrofurantoin in the treatment of women with acute, uncomplicated urinary tract infections (UTI)."	5.09	A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. ( Briefer, C; Echols, RM; Iravani, A; Klimberg, I; Kowalsky, SF; Munera, C, 1999)
"The purpose of this study was to determine the role of enteroaggregative Escherichia coli (EAEC) in the development of traveler's diarrhea and the clinical response of patients with EAEC diarrhea following treatment with ciprofloxacin."	5.09	Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. ( Adachi, JA; Ashley, D; DiCesare, D; DuPont, HL; Ericsson, CD; Glandt, M; Jiang, ZD; Mathewson, JJ, 1999)
"The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany."	5.09	Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000)
"To investigate the effects of an intravenous injection of tobramycin (T) in female patients with acute uncomplicated pyelonephritis treated with ciprofloxacin (CIP) (500 mg bid per os)."	5.09	[Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin]. ( Baron, D; Bonnieux, J; Bourrier, P; Le Conte, P; Lebrin, P; Merit, JB; Potel, G; Simon, N, 2001)
"We compare the bacteriological and clinical efficacy of rufloxacin and ciprofloxacin in patients with acute uncomplicated pyelonephritis."	5.08	Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. ( Bach, D; Cesana, M; Hübner, A; Plétan, Y; van Breukelen, G; van den Berg-Segers, A, 1995)
"A total of 686 adult patients with complicated urinary tract infections were enrolled in a double-blind, randomised, multicentre study to compare sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily) with ciprofloxacin (500 mg orally twice daily) for 10 to 14 days."	5.08	Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. ( di Silverio, F; Geddes, A; Guibert, J; Naber, KG, 1996)
"The efficacy and safety of two fluoroquinolone antimicrobial agents, lomefloxacin and ciprofloxacin, were compared in a randomized, investigator-blinded, multiple-dose study that enrolled 150 adult outpatients with complicated or recurrent urinary tract infections."	5.07	A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. ( Cox, CE, 1992)
"To determine the efficacy of loperamide given with long- and short-course quinolone therapy for treating traveler's diarrhea, 142 US military personnel were randomized to receive a single 750-mg dose of ciprofloxacin with placebo, 750 mg of ciprofloxacin with loperamide, or a 3-day course of 500 mg of ciprofloxacin twice daily with loperamide."	5.07	Treatment of traveler's diarrhea with ciprofloxacin and loperamide. ( DeFraites, R; Echeverria, P; Gelnett, J; Haberberger, RL; Murphy, GS; Petruccelli, BP; Sanchez, JL; Taylor, DN; Walz, S, 1992)
"A prospective, randomised trial was undertaken to compare the efficacy of ciprofloxacin and netilmicin for the treatment of acute pyelonephritis."	5.07	Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. ( Bailey, RR; Lynn, KL; Peddie, BA; Robson, RA; Smith, A, 1992)
"To compare the safety and efficacy of loperamide used in combination with ciprofloxacin or ciprofloxacin alone for the treatment of travelers' diarrhea."	5.07	Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. ( Candler, W; Echeverria, P; McQueen, C; Sanchez, JL; Taylor, DN; Thornton, S, 1991)
"The clinical efficacy and tolerability of ciprofloxacin orally administered at the dosage of 250 mg twice a day was evaluated in 25 patients affected by acute bacterial pharyngotonsillitis."	5.06	Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis. ( D'Errico, G; Esposito, S; Montanaro, C, 1990)
"Two single-dose regimens of ciprofloxacin, 100 and 250 mg, were compared in the treatment of uncomplicated urinary tract infections in women."	5.06	Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. ( Flepp, M; Garlando, F; Lüthy, R; Meier, B; Rietiker, S; Täuber, MG, 1987)
"In a one-year follow-up study, short-term therapy with ciprofloxacin proved to be beneficial in the treatment of chronic bacterial prostatitis, particularly in cases of Escherichia coli prostatitis."	5.06	Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. ( Dalhoff, A; Schiefer, HG; Weidner, W, 1987)
"In a prospective, randomized, double-blind trial, ciprofloxacin (250 mg orally, twice daily) was compared with cinoxacin (500 mg orally, twice daily) in 60 patients with urinary tract infections."	5.06	Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. ( Alpert, ML; Citron, DM; Ginsberg, BP; Goldstein, EJ; Greenway, FL; Kahn, RM, 1987)
"Our study indicated the inhibitory effect of ciprofloxacin and ceftriaxone on the level of hemolysis, suggesting that the sub-inhibitory concentrations of these antibiotics may affect the outcome of infections."	4.12	Characterization of Escherichia coli isolated from urinary tract infection and association between virulence expression and antimicrobial susceptibility. ( Aghaei, A; Ahmadi, E; Ahmadi, S; Derakhshan, S; Nasseri, S, 2022)
"These cases illustrate that cefoxitin is an interesting alternative to carbapenems, even in severe infections such as endocarditis."	4.12	Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis. ( Courtois, R; Danneels, P; Dubée, V; Eveillard, M; Kempf, M; Mahieu, R; Quinqueneau, C; Rihet, C; Vannier, C, 2022)
"To evaluate the impact of cessation of ciprofloxacin prophylaxis during stem cell transplantation for multiple myeloma."	3.91	Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. ( Gabalec, F; Paterova, P; Radocha, J; Zak, P; Zavrelova, A, 2019)
" coli urosepsis was treated with ciprofloxacin for 2 weeks with excellent response."	3.88	IgA-dominant extracapillary proliferative glomerulonephritis following Escherichia coli sepsis in a renal transplant recipient. ( Basic-Jukic, N; Coric, M; Kastelan, Z, 2018)
"Considering the global concern of ciprofloxacin resistance, the aim of this study was to evaluate the characteristics of ciprofloxacin-resistant (CIP-R) Escherichia coli isolated from patients with community-acquired urinary tract infections (UTIs) in Brasília, Brazil."	3.85	Ciprofloxacin resistance in uropathogenic Escherichia coli isolates causing community-acquired urinary infections in Brasília, Brazil. ( de Campos, TA; de Melo, ABF; de Oliveira Martins Júnior, P; de Paulo Martins, V; Gonçalves, LF; Moreira da Silva, RCR; Pitondo-Silva, A, 2017)
"Korean red ginseng (KRG) may be a beneficial adjuvant along with ciprofloxacin to ameliorate devastating effects of epididymo-orchitis (EO) on male fertility."	3.85	Co-administration of ginseng and ciprofloxacin ameliorates epididymo-orchitis induced alterations in sperm quality and spermatogenic cells apoptosis following infection in rats. ( Eskandari, M; Eyni, H; Ghalyanchi Langeroudi, A; Kazemi, M; Rostami, A; Shokri, S; Zeighami, H, 2017)
"Antimicrobial resistance to ciprofloxacin is rising worldwide, especially in bacteria causing urinary tract infections (UTIs)."	3.85	Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population. ( de Visser, H; Goessens, WH; Hofman, A; Kiefte-de Jong, JC; Mulder, M; Stricker, BH; Verbon, A, 2017)
" However, although a single treatment of chitosan followed by ciprofloxacin administration had a marked effect on reducing UPEC titers within the bladder, this treatment failed to prevent relapsing bacteriuria."	3.85	Repeated Treatments with Chitosan in Combination with Antibiotics Completely Eradicate Uropathogenic Escherichia coli From Infected Mouse Urinary Bladders. ( Blango, MG; Erman, A; Hergouth, VK; Kos, MK; Mulvey, MA; Veranic, P, 2017)
"The Infectious Diseases Society of America guidelines recommend either 14 days of trimethoprim-sulfamethoxazole (TMP-SMX) or 7 days of ciprofloxacin for the treatment of pyelonephritis."	3.85	A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis. ( Conley, AT; Fox, MT; Melia, MT; Same, RG; Tamma, PD, 2017)
"Emergence of ciprofloxacin resistant ETEC strains results in a major challenge in current treatment strategies of ETEC diarrhea."	3.83	Resistance Pattern and Molecular Characterization of Enterotoxigenic Escherichia coli (ETEC) Strains Isolated in Bangladesh. ( Azmi, IJ; Begum, YA; Qadri, F; Shahnaij, M; Sharmin, S; Sheikh, A; Svennerholm, AM; Talukder, KA, 2016)
"In this prospective audit, patients were identified as having a low- or high-risk of sepsis based on a questionnaire about established risk factors: previous biopsy; recurrent urine infections; receiving ciprofloxacin in the 12 months prior; travel to South-East Asia or South America in the previous 6 months; or diabetes, immune system impairment or receipt of immunosuppressant drugs."	3.80	Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. ( Blackmore, T; Losco, G; Studd, R, 2014)
" In this patient, however, the clinical course was dramatically complicated by the development of ciprofloxacin-associated rhabdomyolysis."	3.79	Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis. ( Fruhwald, S; Grisold, AJ; Hoenigl, M; Ovcina, I; Valentin, T, 2013)
"Of the 24 patients with EHEC-associated diarrhea, seven received antibiotics before any signs of HUS were present (ciprofloxacin, cefotaxime, amoxicillin and/or metronidazole)."	3.79	Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4-associated diarrhea. ( Fritzsche, C; Geerdes-Fenge, HF; Henschel, J; Höhn, R; Koball, S; Löbermann, M; Mitzner, S; Nürnberg, M; Podbielski, A; Reisinger, EC; Schober, HC, 2013)
"Discordant empirical therapy, mostly with ciprofloxacin, leads to worse early clinical response and longer hospital stay than concordant therapy in community-acquired bacteremic acute pyelonephritis, although it does not affect on overall mortality or clinical cure rate."	3.77	Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. ( Chung, DR; Kim, Y; Lee, SS, 2011)
"The aim of this study was to obtain data on susceptibility patterns of pathogens responsible for both community and hospital urinary tract infections (UTIs); and analyzed risk factors for infection caused by ciprofloxacin-resistant Escherichia coli and extended-spectrum β-lactamase (ESBL)-producing strains in Rwanda."	3.77	Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines. ( Bayingana, C; Claeys, GW; Masaisa, F; Muhirwa, G; Musemakweri, A; Mutesa, L; Muvunyi, CM, 2011)
"Resistance to ciprofloxacin in Escherichia coli from urinary tract infections (UTI) in Denmark is increasing parallel to increased use of fluoroquinolones both in Denmark and in other European countries."	3.77	Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country. ( Christiansen, N; Frimodt-Møller, N; Hansen, LH; Jakobsen, L; Nielsen, L; Stegger, M, 2011)
"To clarify the characteristics of the virulence factors (VFs) of ciprofloxacin resistant Escherichia coli (CFRE) with acute uncomplicated cystitis (AUC), we determined the VFs and the phylogenetic background of all 54 CFRE strains and the 55 randomly selected ciprofloxacin sensitive E."	3.76	Virulence characteristics and phylogenetic background of ciprofloxacin resistant Escherichia coli in the urine samples from Korean women with acute uncomplicated cystitis. ( Cho, IR; Cho, YH; Kim, CS; Kim, ME; Lee, G, 2010)
"Pregnant rabbits were treated with ciprofloxacin alone or with gentamicin in a model of Escherichia coli chorioamnionitis, and the results were compared with those for untreated rabbits."	3.75	Efficacy of ciprofloxacin in an experimental model of Escherichia coli chorioamnionitis in rabbits. ( Caillon, J; Gras-Le Guen, C; Jacqueline, C; Joram, N; Launay, E; Miegeville, AF; Potel, G; Roze, JC, 2009)
"The aims of this study were to investigate the prevalence of qnrA, qnrB, and qnrS determinants and their molecular characteristics in ciprofloxacin-resistant isolates of Escherichia coli and Klebsiella pneumoniae from urinary tract infections (UTI) in Korea."	3.74	High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections in Korea. ( Chang, CL; Jung, HJ; Kim, HR; Lee, JN; Lee, JY; Shin, JH, 2008)
"Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E."	3.74	In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. ( Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007)
"The aim of this study was to evaluate the efficiency of methylene blue (MB) in preventing renal scar formation after the induction of pyelonephritis (PNP) in a rat model with delayed antimicrobial therapy."	3.74	The effects of methylene blue on renal scarring due to pyelonephritis in rats. ( Aksu, B; Aydin, S; Ayvaz, S; Durmus-Altun, G; Gurcan, S; Inan, M; Kanter, M; Oz Puyan, F; Pul, M; Uzun, H, 2007)
"We investigated the effects of epididymo-orchitis and ciprofloxacin on rat testicular histology and spermatogenesis."	3.74	Effect of experimentally induced Escherichia coli epididymo-orchitis and ciprofloxacin treatment on rat spermatogenesis. ( Demir, A; Findik, A; Onol, FF; Sirvanci, S; Tarcan, T; Türker, P, 2007)
"The current results suggest that fluoroquinolone prophylaxis for patients with febrile neutropenia may be abandoned safely in areas with a high prevalence of ciprofloxacin-resistant enterobacteria."	3.72	Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. ( Dalmau, D; Estany, C; Estrada, C; Garau, J; Gomez, L; Marquez, M; Martí, JM; Xercavins, M, 2003)
"The prevalence of hemolysin, type 1 fimbriae, P fimbriae, cytotoxic necrotizing factor-1 (CNF-1), aerobactin, and autotransporter toxin (sat) was analyzed by polymerase chain reaction and phenotypic assays of 42 epidemiologically unrelated Escherichia coli strains causing acute pyelonephritis in women (21 nalidixic acid-susceptible and 21 nalidixic acid-resistant strains) and 58 E."	3.71	Are quinolone-resistant uropathogenic Escherichia coli less virulent? ( Barranco, M; Horcajada, JP; Mensa, J; Moreno, A; Ruiz, J; Simon, K; Velasco, M; Vila, J, 2002)
"The emergence and evolution of quinolone-resistant Escherichia coli in faeces of patients with prostatitis treated with high-dose oral ciprofloxacin for 1 month were studied."	3.71	Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. ( Horcajada, JP; Martínez, JA; Mensa, J; Moreno-Martínez, A; Ruiz, J; Sánchez, M; Soriano, E; Vila, J, 2002)
"To detect if isolates susceptible to quinolones already carry mutations in the gyrA and parC genes, we selected 12 ciprofloxacin-susceptible Escherichia coli strains collected from patients with urinary tract infections in Latin America in 1998, as part of ongoing SENTRY Antimicrobial Surveillance Program."	3.70	Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. ( Gales, AC; Gordon, KA; Jones, RN; Pfaller, MA; Wilke, WW, 2000)
"From 1988 to 1992, 27 of 855 cases of Escherichia coli bacteremia in nonneutropenic adult patients observed at our hospital were due to ciprofloxacin-resistant (CIPRO-R) strains."	3.69	Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. ( Albareda, JM; Ariza, J; Pallares, R; Peña, C; Pujol, M; Tubau, F, 1995)
"Detection of Shigella organisms and enteroinvasive Escherichia coli (EIEC) by polymerase chain reaction (PCR) was evaluated in 20 patients with dysentery before and in 17 of the 20 after treatment with ciprofloxacin."	3.68	Detection of Shigellae and enteroinvasive Escherichia coli by amplification of the invasion plasmid antigen H DNA sequence in patients with dysentery. ( Eampokalap, B; Echeverria, P; Hoge, CW; Murphy, GS; Sethabutr, O; Venkatesan, M, 1993)
"A total of 16 men suffering from refractory chronic bacterial prostatitis caused by Escherichia coli was treated with ciprofloxacin for 4 weeks."	3.68	Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months. ( Brähler, E; Schiefer, HG; Weidner, W, 1991)
"The ciprofloxacin efficacy was compared to that of tobramycin in an Escherichia coli pyelonephritis model in rat."	3.68	Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin. ( Grise, G; Le Boete, I; Lecomte, F; Lemeland, JF; Thauvin-Eliopoulos, C, 1990)
"Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa."	3.67	Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986)
" The only significant difference in pharmacokinetic parameters between the two formulations was seen in the rate constant of absorption, which was approximately 50% greater with the IR formulation."	2.71	Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. ( Dalhoff, A; Forrest, A; Meagher, AK; Schentag, JJ; Stass, H, 2004)
"Oral ciprofloxacin is a cost-effective prophylactic agent for high-risk ERCP."	2.69	Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients. ( Alveyn, CG; Davis, AJ; Kolios, G; Robertson, DA, 1998)
"It is likely that EAggEc are a treatable cause of diarrheal disease in some persons with HIV and no other apparent enteric pathogen."	2.69	Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus. ( Acheson, D; Blais, V; Gerrior, J; Mayer, H; Wanke, CA, 1998)
"coli bacteremia were due to QREC."	2.69	Emergence and dissemination of quinolone-resistant Escherichia coli in the community. ( Coll, I; Garau, J; Gómez-Vera, JR; Llovet, T; Rodríguez-Carballeira, M; Ruíz-Bremón, A; Vidal, D; Xercavins, M, 1999)
"Ciprofloxacin was used for the treatment of refractory chronic bacterial prostatis."	2.67	Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin. ( Schiefer, HG; Weidner, W, 1991)
" The use of antibiotics with favourable pharmacokinetic/pharmacodynamic profiles and convenient dosing schedules, which effectively increase bacterial eradication and patient compliance, can help to curb the current epidemic of resistance and reduce the rate of clinical failure associated with resistance."	2.42	Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. ( Elkharrat, D; Naber, KG; Palou, J; Talan, DA, 2004)
"A residual psoas abscess was drained percutaneously under CT guidance."	2.41	Psoas abscess associated with infected total hip arthroplasty. ( Buttaro, M; González Della Valle, A; Piccaluga, F, 2002)
"Complex cysts were observed by ultrasonography (in four of eight patients), computed tomography (in six of nine), and magnetic resonance imaging (in two of two)."	2.38	Hepatic cyst infection in autosomal dominant polycystic kidney disease. ( Brown, ML; Gross, JB; Hattery, RR; Telenti, A; Torres, VE; Van Scoy, RE, 1990)
" However, conventional antibiotic combinations have some limitations such as the low bioavailability and the rise of resistant strains."	1.72	Nanosized Combined Antimicrobial Drugs Decreased Emergence of Resistance in ( Abd El-Baky, RM; Aly, SA; Elsabahy, M; Hadiya, S; Ibrahem, RA, 2022)
"CIP displayed linear PK with dose proportional increase in Cmax and AUCinf in plasma."	1.56	Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice. ( Hiremath, S; Jayaraman, R; Nanjundappa, M; Pawar, A; Puttarangappa, P; Puttaswamy, R; Reniguntla, MK; Yedle, R, 2020)
" Vitamin C, probably due to its strong antioxidant properties, could improve and partially counteract the toxic effect of UV-A on oxidative stress parameters and prevent the damage in rat's brain tissues."	1.56	The possible neurobehavioral protective effects of natural antioxidant against phototoxicity attenuation of antimicrobial quinolone group in rats. ( Mansour, HA; Masoud, MA; Sheded, MS; Yahia, R, 2020)
" The PASS online and SwissADME programmes were used for the prediction of biological activities and oral bioavailability of cuminaldehyde."	1.56	Cuminaldehyde potentiates the antimicrobial actions of ciprofloxacin against Staphylococcus aureus and Escherichia coli. ( Almeida, VSS; Carvalho Júnior, AR; da Silveira, BC; de Araújo, TS; de Oliveira, NMT; de Souza, CD; Fernandes, ES; Ferro, TAF; Gonzaga, LF; Maria-Ferreira, D; Martins, WC; Mendes, SJF; Monteiro-Neto, V; Pessoa, JFV; Pontes, JP; Santos, DM; Sousa, NCF, 2020)
"Ciprofloxacin resistance was found in 5."	1.51	Antibiotic resistance patterns of Escherichia coli in migrants vs non-migrants: a study of 14 561 urine samples. ( Friedland, JS; Hargreaves, S; Nellums, LB; Nielsen, RT; Norredam, M; Sloth, LB; Østergaard, C, 2019)
"Ampicillin (84."	1.48	Multidrug resistance, prevalence and phylogenetic analysis of genes encoding class II and III integrons in clinically isolated Escherichia coli. ( Abdelwahab, SI; Dafalla, OME; Homeida, HE; Taha, MME, 2018)
"The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data."	1.46	A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. ( Conil, JM; Friberg, LE; Georges, B; Houin, G; Karlsson, MO; Khachman, D; Laffont, CM; Nielsen, EI; Sadiq, MW, 2017)
" Population pharmacokinetic analysis and Monte Carlo simulation was undertaken using Pmetrics."	1.43	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ( Lefrant, JY; Lipman, J; Louart, B; Muller, L; Roberts, JA; Roger, C; Wallis, SC, 2016)
"Ciprofloxacin treatment reorganized microbiota populations; however, the original structure was largely restored at one and three month follow-up visits."	1.43	Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment. ( Astrovskaya, I; Bravo, HC; Chakraborty, S; Harro, C; Li, S; Lindsay, BR; Parkhill, J; Paulson, JN; Pop, M; Sack, DA; Stine, OC; Walker, AW; Walker, RI, 2016)
"The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo."	1.43	Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016)
"Empirical and prolonged antimicrobial treatment of urinary tract infections caused by Escherichia coli is associated with the emergence of bacterial resistance, and not all countries have strict policies against the indiscriminate use of drugs in order to prevent resistance."	1.43	Antibiotic Resistance of Bacteria Involved in Urinary Infections in Brazil: A Cross-Sectional and Retrospective Study. ( Araújo, MC; De Resende, EA; Lazo-Chica, JE; Miguel, CB; Nogueira, AP; Oliveira, CJ; Paulino, Tde P; Rodrigues, WF; Soares, Sde C; Ueira-Vieira, C, 2016)
"Cefepime is a fourth-generation cephalosporin that is widely prescribed with few severe adverse reactions reported."	1.42	Cefepime induced acute interstitial nephritis--a case report. ( Chavada, R; Howlin, K; Mac, K; Paull, S; Wong, J, 2015)
"Ciprofloxacin alone was associated with significantly more infections than ciprofloxacin plus an additional agent (P = 0."	1.42	Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy. ( Gupta, K; Lerner, L; Marino, K; Orlando, R; Parlee, A; Strymish, J, 2015)
"One patient developed Fusarium infection."	1.40	Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country. ( Adil, SN; Ali, N; Shaikh, MU, 2014)
"Ciprofloxacin resistance was associated with certain specific clones, among them the globally distributed clonal Group A."	1.40	High levels of multiresistance in quinolone resistant urinary tract isolates of Escherichia coli from Norway; a non clonal phenomen? ( Allum, AG; Grude, N; Henriksen, IH; Jenkins, A; Kristiansen, BE; Strand, L, 2014)
"06 µg/ml and attained a Tmax of 2."	1.40	Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens. ( Abo El-Ela, FI; El-Banna, HA; El-Gendy, AA; Radi, AM; Tohamy, MA, 2014)
"A 62-yr-old woman with an autosomal dominant polycystic kidney disease (ADPKD) was admitted to our hospital for further evaluation of intermittent fever, nausea and left flank discomfort."	1.39	Successfully treated Escherichia coli-induced emphysematous cyst infection with combination of intravenous antibiotics and intracystic antibiotics irrigation in a patient with autosomal dominant polycystic kidney disease. ( Ahn, C; Cho, C; Hwang, YH; Kim, DK; Kim, H; Lee, J; Lee, S; Oh, KH; Park, HC, 2013)
" When the most potent representative, an indolinylphenyl mannoside, was administered in a mouse model at the low dosage of 1 mg/kg (corresponding to approximately 25 μg/mouse), the minimal therapeutic concentration to prevent UTI was maintained for more than 8 h."	1.38	Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. ( Abgottspon, D; Ernst, B; Haug, M; Jiang, X; Kleeb, S; Rabbani, S; Scharenberg, M; Schwardt, O; Wittwer, M, 2012)
"The antibiotic treatment rate of chronic bacterial prostatitis (CBP) is low, and long-term administration can result in adverse events and bacterial resistance."	1.38	Preventive effect of selenium on chronic bacterial prostatitis. ( Cho, YH; Ha, US; Kim, HW; Kim, SJ; Lee, SJ; Woo, JC; Yoon, BI, 2012)
"For ciprofloxacin the ORs were 2."	1.38	Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model. ( Bennett, K; Cormican, M; Hanahoe, B; Murphy, AW; Tansey, S; Vellinga, A, 2012)
"Enrofloxacin was absorbed after oral administration in infected animals but with large inter-individual variations."	1.37	Pharmacokinetic-pharmacodynamic indices of enrofloxacin in Escherichia coli O78/H12 infected chickens. ( Haritova, A; Lashev, L; Lutckanov, M; Petrov, V; Urumova, V, 2011)
"Carbapenems were consistently the most active drugs tested."	1.36	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob ( Badal, RE; Baquero, F; Bouchillon, SK; Cantón, R; Hawser, SP; Hoban, DJ, 2010)
"The proven shigellosis as well as the strong suspicion have to be treated promptly with antibiotics, mainly azithromycin."	1.35	[Bacterial diarrheas and antibiotics: European recommendations]. ( Cohen, R; Gendrel, D, 2008)
"Glenohumeral septic arthritis is rare and usually a result of Staphylococcus aureus infection."	1.35	Bilateral glenohumeral septic arthritis secondary to retroperitoneal abscess. ( Evans, RO; Ferran, NA; Lyons, K; Rodriguez, CL, 2009)
" However, the treatment outcome is not ideal and long-term administration of antibiotics can result in adverse effects and bacterial resistance."	1.35	Synergistic effect between lycopene and ciprofloxacin on a chronic bacterial prostatitis rat model. ( Cho, YH; Han, CH; Kang, SH; Kim, SW; Sohn, DW; Yang, CH, 2008)
" coli resistant to nalidixic acid, it was necessary to evaluate the MIC of ciprofloxacin in order to asses the optimal dosage of ciprofloxacin."	1.35	Optimization of the use of ciprofloxacin. ( Aubert, G; Carricajo, A; Fonsale, N; Vautrin, AC, 2009)
"Rifaximin has been evaluated in adults for treatment of bacterial enteritis and has a good record for safety and efficacy, but it has not been evaluated extensively in children with gastroenteritis."	1.34	Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. ( Chen, J; Cleary, TG; Gonzales, E; Ochoa, TJ; Walker, CM, 2007)
"military personnel being treated for diarrhea were evaluated."	1.33	Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin. ( Frenck, RW; Putnam, SD; Riddle, MS; Rockabrand, DR; Rozmajzl, PJ; Sanders, JW; Tribble, DR, 2005)
" The relationship between the efficacies of these 3 dosage schemes could have been predicted by AUC above MIC and AUIC, but not by AUC/MIC or time above MIC."	1.33	Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval? ( Czock, D; Rasche, FM, 2005)
"The development of toxic megacolon as a complication of infectious colitis is rare."	1.33	Toxic megacolon complicating Escherichia coli O157 infection. ( Koerner, RJ; McElroy, J; Nayar, DM; Pai, P; Vetrivel, S, 2006)
"An in vitro kinetic model was used to measure MPC with static antibiotic concentrations and to test different dosing profiles to study pharmacokinetics/pharmacodynamics indices important to prevent the growth of resistant mutants."	1.33	Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. ( Cars, O; Hughes, D; Komp Lindgren, P; Marcusson, LL; Olofsson, SK, 2006)
"Ciprofloxacin uptake was determined spectrophotometrically using the quinolone accumulation assay."	1.33	Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. ( Chenia, HY; Pillay, B; Pillay, D, 2006)
"coli bacteremia have not changed, yet the mortality was lower in our series."	1.32	[Bacteremia due to Escherichia coli: epidemiological analysis and sensitivity to antibiotics in a county hospital]. ( García-Somoza, D; Gudiol, F; Javaloyas, M, 2003)
"Ciprofloxacin was the only agent studied that demonstrated a consistent stepwise increase in resistance from 1995 (0."	1.31	Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. ( Jones, ME; Karlowsky, JA; Kelly, LJ; Sahm, DF; Thornsberry, C, 2002)
"Cholangitis is a frequent complication of biliary stents."	1.31	Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. ( Esber, E; Fogel, EL; Kalayci, C; Lehman, GA; Rerknimitr, R; Sherman, S, 2002)
"Vertebral osteomyelitis was diagnosed and treated with antibiotics."	1.31	Vertebral osteomyelitis: a rare complication of transvaginal ultrasound-guided oocyte retrieval. ( Almog, B; Amit, A; Azem, F; Bar-Am, A; Rimon, E; Yovel, I, 2000)
"To compare the antimicrobial effects (AMEs) of gemifloxacin (GEM) and ciprofloxacin (CIP) on Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, a series of pharmacokinetic profiles of GEM (a single dose with the half-life (T(1/2)) of 7."	1.31	Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. ( Firsov, AA; Vostrov, SN; Zinner, SH, 2000)
"Bacterial infections were seen in 37% of patients with acute pancreatitis."	1.31	Incidence, spectrum and antibiotic sensitivity pattern of bacterial infections among patients with acute pancreatitis. ( Bohidar, NP; Garg, PK; Kapil, A; Khanna, S; Tandon, RK, 2001)
"Focal xanthogranulomatous pyelonephritis is an unusual form of chronic renal infection that is difficult to diagnose prior to surgery."	1.31	[Pseudotumoral xanthogranulomatous pyelonephritis: diagnosis with percutaneous biopsy and success of conservative treatment]. ( Andrianne, R; Boverie, J; de Leval, J; Reul, O; Waltregny, D, 2001)
"Sarafloxacin was noted to be very active and comparable to ciprofloxacin and enrofloxacin for inhibiting 823 strains from a wide variety of species at < or = 1 or < or = 2 micrograms/mL."	1.30	In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group. ( Erwin, ME; Jones, RN, 1998)
" coli develop in the presence of long-term selective ciprofloxacin pressure at a dosing regimen of 250 mg bid for more than 20 days and that treatment with a broad spectrum antimicrobial for more than three days favours the selection of multi-resistant E."	1.30	Molecular epidemiology of multi-resistant Escherichia coli. ( Barrett, SP; Cheasty, T; Guyot, A; Hampton, MD; Threlfall, EJ, 1999)
"Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic bone marrow or peripheral blood stem cell transplantation at Veterans General Hospital, Kaohsiung from February 1997."	1.30	Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal. ( Hsueh, EJ; Wang, YC; Wu, H; Yeh, SP; Yu, MS, 1999)
"Ciprofloxacin is a broad spectum quinolone antibiotic."	1.29	Prolonged bleeding time during ciprofloxacin therapy. ( Pilmore, HL; Walker, RJ, 1995)
"Ciprofloxacin appears to be a safe and effective option for treating renal cyst infections."	1.29	High-dose ciprofloxacin in the treatment of a renal cyst infection. ( Deepe, G; Healy, DP; Rossi, SJ; Savani, DV, 1993)
"Thus, malakoplakia can be cured by antibiotic treatment."	1.28	Ciprofloxacin for treatment of malakoplakia. ( van Furth, R; van't Wout, JW; Wertheimer, PA; Zwartendijk, J, 1992)
"This is the first reported case of malakoplakia arising from conjunctiva, although three others have involved the ocular adnexa."	1.28	Medical management of ocular malakoplakia. ( Dickinson, J; Sandford-Smith, JH; Simpson, C; Strong, NP; Young, FI, 1992)
"Ciprofloxacin was rapidly bactericidal in vivo and was significantly more effective in reducing the numbers of E."	1.27	Efficacy of ciprofloxacin in experimental arthritis caused by Escherichia coli--in vitro-in vivo correlations. ( Anderson, D; Bayer, AS; Norman, D, 1985)
" Adverse reactions were spontaneously reported by four of the 28 patients (14%) and by 11 (39%) after detailed inquiry."	1.27	Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. ( Boerema, J; Boll, B; Branolte, J; Muytjens, H, 1985)
"Ciprofloxacin was tested in the acute and chronic experimental E."	1.27	[Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats]. ( Boness, J; Marre, R; Schulz, E; Tietgen, K, 1986)
"Ciprofloxacin was compared with ceftriaxone in a rabbit model of septic arthritis caused by Escherichia coli."	1.27	Comparative efficacy of ciprofloxacin and ceftriaxone in experimental arthritis caused by Escherichia coli. ( Bayer, AS; Blomquist, IK; Norman, DC, 1986)
"Ciprofloxacin was more effective than norfloxacin or pefloxacin and comparable in efficacy to ofloxacin."	1.27	Efficacy of ciprofloxacin in stationary-phase bacteria in vivo. ( Voigt, WH; Zeiler, HJ, 1987)
"Fleroxacin was more potent than norfloxacin."	1.27	Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli. ( Fabrig, J; Hof, H, 1988)
" The dosage was 2 X 500 mg ciprofloxacin orally every 12 h for 7."	1.27	Is pelvic inflammatory disease an indication for treatment with ciprofloxacin? ( Chyský, V; Hägele, D, 1988)
"Treatment with ciprofloxacin at 0."	1.27	Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. ( Bloom, R; Fu, KP; Gregory, FJ; Hung, PP; Vince, T, 1987)
"Norfloxacin was ineffective at 200 mg/kg per day against E."	1.27	In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986)
" The terminal serum elimination half-life averaged 4."	1.27	Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. ( Dudley, MN; Ericson, J; Gilbert, D; Mandler, HD; Mayer, KH; Zinner, SH, 1987)

Research

Studies (513)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Number of All (First and Recurrent) Incident Urinary Catheter-associated Urinary Tract Infections

Timeframe	Studies, this research(%)	All Research%
pre-1990	24 (4.68)	18.7374
1990's	67 (13.06)	18.2507
2000's	123 (23.98)	29.6817
2010's	229 (44.64)	24.3611
2020's	70 (13.65)	2.80

Authors	Studies
Segawa, J	1
Kitano, M	1
Kazuno, K	1
Matsuoka, M	1
Shirahase, I	1
Ozaki, M	1
Matsuda, M	1
Tomii, Y	1
Kise, M	1
Cooper, CS	1
Klock, PL	1
Chu, DT	2
Hardy, DJ	1
Swanson, RN	1
Plattner, JJ	1
Ziegler, CB	2
Bitha, P	1
Kuck, NA	2
Fenton, TJ	1
Petersen, PJ	1
Lin, YI	2
Moran, DB	1
Dunne, TS	1
Frigola, J	1
Vañó, D	1
Torrens, A	1
Gómez-Gomar, A	1
Ortega, E	1
García-Granda, S	1
Castanheira, M	1
Pereira, AS	1
Nicoletti, AG	1
Pignatari, AC	2
Barth, AL	1
Gales, AC	2
Mendonça, N	1
Leitão, J	1
Manageiro, V	1
Ferreira, E	1
Caniça, M	1
Ikonomidis, A	2
Labrou, M	1
Afkou, Z	1
Maniatis, AN	2
Sofianou, D	2
Tsakris, A	1
Pournaras, S	2
Ochoa, TJ	2
Chen, J	1
Walker, CM	1
Gonzales, E	1
Cleary, TG	1
Yamane, K	2
Wachino, J	2
Suzuki, S	2
Kimura, K	1
Shibata, N	1
Kato, H	1
Shibayama, K	1
Konda, T	1
Arakawa, Y	3
Sevillano, D	1
Aguilar, L	1
Alou, L	1
Giménez, MJ	1
Torrico, M	1
González, N	1
Cafini, F	1
Relaño, MT	1
Coronel, P	1
Prieto, J	1
Doi, Y	2
Adams-Haduch, JM	1
Paterson, DL	2
Baudry, PJ	1
Nichol, K	1
DeCorby, M	1
Mataseje, L	1
Mulvey, MR	1
Hoban, DJ	3
Zhanel, GG	2
Vasilaki, O	1
Ntokou, E	1
Frantzidou, F	1
Alexiou-Daniel, S	1
Kiratisin, P	1
Apisarnthanarak, A	1
Laesripa, C	1
Saifon, P	1
Tumbarello, M	1
Sali, M	1
Trecarichi, EM	1
Leone, F	1
Rossi, M	1
Fiori, B	1
De Pascale, G	1
D'Inzeo, T	1
Sanguinetti, M	1
Fadda, G	1
Cauda, R	1
Spanu, T	1
Cattoir, V	2
Poirel, L	1
Nordmann, P	2
Yagci, D	1
Yoruk, F	1
Azap, A	1
Memikoglu, O	1
Allou, N	1
Cambau, E	2
Massias, L	2
Chau, F	3
Fantin, B	3
Peirano, G	1
Richardson, D	1
Nigrin, J	1
McGeer, A	1
Loo, V	1
Toye, B	1
Alfa, M	2
Pienaar, C	1
Kibsey, P	1
Pitout, JD	1
Bortolaia, V	1
Guardabassi, L	2
Trevisani, M	1
Bisgaard, M	1
Venturi, L	1
Bojesen, AM	1
Blango, MG	2
Mulvey, MA	2
Goren, MG	1
Navon-Venezia, S	1
Chmelnitsky, I	1
Carmeli, Y	2
Hawser, SP	1
Bouchillon, SK	1
Badal, RE	1
Cantón, R	2
Baquero, F	2
Tängdén, T	1
Cars, O	2
Melhus, A	1
Löwdin, E	1
Auer, S	1
Wojna, A	1
Hell, M	1
Al-Trawneh, SA	1
Zahra, JA	1
Kamal, MR	1
El-Abadelah, MM	1
Zani, F	1
Incerti, M	1
Cavazzoni, A	1
Alfieri, RR	1
Petronini, PG	1
Vicini, P	1
Jiang, X	2
Abgottspon, D	2
Kleeb, S	2
Rabbani, S	2
Scharenberg, M	2
Wittwer, M	1
Haug, M	1
Schwardt, O	2
Ernst, B	2
Suresh, N	1
Nagesh, HN	1
Renuka, J	1
Rajput, V	1
Sharma, R	1
Khan, IA	1
Kondapalli Venkata Gowri, CS	1
Pang, L	2
Mayer, K	1
Eris, D	1
Sigl, A	1
Preston, RC	1
Zihlmann, P	1
Sharpe, T	1
Jakob, RP	1
Hutter, AS	1
Navarra, G	1
Smiesko, M	1
Lüdin, N	1
Bezençon, J	1
Maier, T	1
Wei, W	1
Liu, Q	1
Li, ZZ	1
Shi, WK	1
Fu, X	1
Liu, J	2
Zhu, X	2
Wang, XC	1
Xu, N	1
Li, TF	1
Jiang, FR	1
Xiao, ZP	1
Zhu, HL	1
Jin, Z	1
Wang, L	2
Gao, H	1
Zhou, YH	1
Liu, YH	1
Tang, YZ	1
Panchaud, P	1
Surivet, JP	1
Diethelm, S	1
Blumstein, AC	1
Gauvin, JC	1
Jacob, L	1
Masse, F	1
Mathieu, G	1
Mirre, A	1
Schmitt, C	1
Enderlin-Paput, M	1
Lange, R	1
Gnerre, C	1
Seeland, S	1
Herrmann, C	1
Locher, HH	1
Seiler, P	1
Ritz, D	1
Rueedi, G	1
Rahuman, HBH	1
Dhandapani, R	1
Palanivel, V	1
Thangavelu, S	1
Paramasivam, R	1
Muthupandian, S	1
Kerkez, I	1
Tulkens, PM	1
Tenson, T	1
Van Bambeke, F	1
Putrinš, M	1
Mumtaz, K	1
Munir, S	1
Muddassir, M	1
Raza, A	1
Waqas, K	1
Shoaib Ahmed, S	1
Malik, A	1
Haider Naqvi, SZ	1
Phan, MD	1
Peters, KM	1
Alvarez Fraga, L	1
Wallis, SC	2
Hancock, SJ	1
Nhu, NTK	1
Forde, BM	1
Bauer, MJ	1
Beatson, SA	1
Lipman, J	2
Schembri, MA	1
Ten Doesschate, T	2
Kuiper, S	1
van Nieuwkoop, C	2
Hassing, RJ	1
Ketels, T	1
van Mens, SP	2
van den Bijllaardt, W	1
van der Bij, AK	1
Geerlings, SE	4
Koster, A	1
Koldewijn, EL	1
Branger, J	1
Hoepelman, AIM	2
van Werkhoven, CH	1
Bonten, MJM	2
Svenningsen, MS	1
Svenningsen, SL	1
Sørensen, MA	1
Mitarai, N	1
Mofolorunsho, KC	1
Ocheni, HO	1
Aminu, RF	1
Omatola, CA	1
Olowonibi, OO	1
Diaz-Diaz, S	1
Recacha, E	2
García-Duque, A	1
Docobo-Pérez, F	3
Blázquez, J	2
Pascual, A	8
Rodríguez-Martínez, JM	5
Rodríguez, I	1
Figueiredo, AS	1
Sousa, M	1
Aracil-Gisbert, S	1
Fernández-de-Bobadilla, MD	1
Lanza, VF	1
Rodríguez, C	2
Zamora, J	1
Loza, E	1
Mingo, P	1
Brooks, CJ	1
Coque, TM	1
Huan, Y	1
Kong, Q	1
Tang, Q	1
Wang, Y	3
Mou, H	1
Ying, R	1
Li, C	1
de Lastours, V	1
El Meouche, I	1
Beghain, J	1
Chevret, D	1
Aubert-Frambourg, A	1
Clermont, O	1
Royer, G	1
Bouvet, O	1
Denamur, E	2
Dobbyn, D	1
Zeggil, T	1
Kudrowich, B	1
Beahm, NP	1
Derakhshan, S	1
Ahmadi, S	1
Ahmadi, E	1
Nasseri, S	1
Aghaei, A	1
Aroso, RT	1
Dias, LD	1
Blanco, KC	1
Soares, JM	1
Alves, F	1
da Silva, GJ	1
Arnaut, LG	1
Bagnato, VS	1
Pereira, MM	1
Frisbie, L	1
Weissman, SJ	1
Kapoor, H	1
D'Angeli, M	1
Salm, A	1
Radcliff, J	1
Rabinowitz, P	1
Haji Hossein Tabrizi, A	1
Habibi, M	1
Foroohi, F	1
Mohammadian, T	1
Asadi Karam, MR	1
Sørum, V	2
Øynes, EL	1
Møller, AS	1
Harms, K	1
Samuelsen, Ø	2
Podnecky, NL	2
Johnsen, PJ	2
Jalil, MB	1
Al Atbee, MYN	1
Salm, J	1
Salm, F	1
Arendarski, P	1
Kramer, TS	1
Santona, A	1
Sumbana, JJ	1
Fiamma, M	1
Deligios, M	1
Taviani, E	1
Simbine, SE	1
Zimba, T	1
Sacarlal, J	1
Rubino, S	1
Paglietti, B	1
Prasada Rao, CMM	1
Vennila, T	1
Kosanam, S	1
Ponsudha, P	1
Suriyakrishnaan, K	1
Alarfaj, AA	1
Hirad, AH	1
Sundaram, SR	1
Surendhar, PA	1
Selvam, N	1
Danneels, P	1
Rihet, C	1
Vannier, C	1
Quinqueneau, C	1
Courtois, R	1
Kempf, M	1
Eveillard, M	1
Mahieu, R	1
Dubée, V	1
Hadiya, S	1
Ibrahem, RA	1
Abd El-Baky, RM	1
Elsabahy, M	1
Aly, SA	2
Seo, K	1
Do, KH	1
Lee, WK	1
Elsby, DT	1
Zadoks, RN	1
Boyd, K	1
Silva, N	1
Chase-Topping, M	1
Mitchel, MC	1
Currie, C	1
Taggart, MA	1
Matta-Chuquisapon, J	1
Valencia-Bazalar, E	1
Sevilla-Andrade, C	1
Barrón-Pastor, HJ	1
De Jong, A	1
El Garch, F	1
Hocquet, D	1
Prenger-Berninghoff, E	1
Dewulf, J	1
Migura-Garcia, L	1
Perrin-Guyomard, A	1
Veldman, KT	1
Janosi, S	1
Skarzynska, M	1
Simjee, S	1
Moyaert, H	1
Rose, M	2
Kudinha, T	1
Kong, F	1
Aglomasa, BC	1
Adu-Asiamah, CK	1
Asiedu, SO	1
Kini, P	1
Amewu, EKA	1
Boahen, KG	1
Wireko, S	1
Amponsah, IK	1
Boakye, YD	1
Boamah, VE	1
Kwarteng, A	1
Aditya, V	2
Kotian, A	2
Sanil, A	1
Thaseena, PM	1
Karunasagar, I	3
Deekshit, VK	3
Gu, S	1
Lai, J	1
Kang, W	1
Li, Y	1
Ji, T	1
Feng, J	1
Zhao, L	1
Li, Z	2
Dong, L	1
Hou, G	1
Zhu, Y	1
He, C	1
Geng, H	1
Pang, D	1
Revitt-Mills, SA	1
Wright, EK	1
Vereker, M	1
O'Flaherty, C	1
McPherson, F	1
Dawson, C	1
van Oijen, AM	1
Robinson, A	1
Frimodt-Møller, N	7
Simonsen, GS	3
Larsen, AR	3
Kahlmeter, G	3
Nielsen, RT	2
Andersen, CØ	1
Schønheyder, HC	1
Petersen, JH	1
Knudsen, JD	1
Jarløv, JO	1
Norredam, M	2
Vanstokstraeten, R	1
Piérard, D	1
Crombé, F	1
De Geyter, D	1
Wybo, I	1
Muyldermans, A	1
Seyler, L	1
Caljon, B	1
Janssen, T	1
Demuyser, T	1
Badal, BD	1
Silvey, S	1
Dragilev, L	1
O'Leary, JG	1
Morgan, TR	1
Cheung, R	1
Patel, A	1
Rogal, S	1
Patton, H	1
Nobbe, A	1
Jakab, SS	1
Patel, N	1
Bajaj, JS	1
Papouskova, A	1
Rychlik, I	1
Harustiakova, D	1
Cizek, A	3
Cho, YY	1
Ko, KS	3

Trial	Phase	Enrollment	Study Type	Start Date	Status
Incidence of Fluoroquinolone Resistant Bacteria in Patients Undergoing Prostate Biopsy[NCT02140502]		200 participants (Actual)	Observational [Patient Registry]	2015-05-31	Completed
Epidemiology of ST131 in Besançon University Hospital[NCT02853708]		300 participants (Actual)	Observational	2015-06-30	Completed
Targeted Infection Control Program (TIP) to Reduce Resistant Pathogens and Infections[NCT01062841]		418 participants (Actual)	Interventional	2010-05-31	Completed
Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting[NCT05702762]	Phase 2	160 participants (Anticipated)	Interventional	2022-10-01	Recruiting
The Impact of the Implementation of Academic Detailing Interventions Based on Scientific Evidence on the Prescribing of Antimicrobial Drugs in Primary Health Care[NCT05090475]		16 participants (Actual)	Interventional	2020-04-01	Completed
Reduction of the Duration of Antibiotic Guided by Procalcitonin in Infections Lungs of Hospitalized Elderly: a Randomized[NCT02173613]		117 participants (Actual)	Interventional	2012-08-31	Terminated
A Randomized Controlled Trial to Investigate the Infectious Outcomes of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of Needle Tip During Transrectal Ultrasound Guided Prostate Biopsy[NCT03879486]		1,257 participants (Actual)	Interventional	2017-05-31	Completed
Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)[NCT02650518]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2015-12-31	Recruiting
A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531]	Phase 2	2 participants (Actual)	Interventional	2007-03-31	Terminated (stopped due to Lack of enrollment)
A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis[NCT00583076]	Phase 2	19 participants (Actual)	Interventional	2007-02-28	Completed
Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study[NCT02591901]	Phase 2	48 participants (Actual)	Interventional	2018-04-06	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]